Business
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
TOKYO, May 28, 2026--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26).
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/7a90af2ccd66c9237b77ee9b23edb0f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/igAP1X6uGDDsjeJpYRhD9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0OA--/https://media.zenfs.com/en/business-wire.com/7a90af2ccd66c9237b77ee9b23edb0f4","width":480,"height":474},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/WM3oWC4WmNO6j5L7tb38Vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTYzMg--/https://media.zenfs.com/en/business-wire.com/7a90af2ccd66c9237b77ee9b23edb0f4","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership","length":184,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer","length":198,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":382,"olType":false},{"type":"text","content":"TOKYO, May 28, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26).","length":253,"tagName":"p"},{"type":"text","content":"Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients with cancer, including new analyses from five landmark trials in breast and gastric cancer, including the DESTINY-Breast05 (#516), DESTINY-Breast06 (#1063), DESTINY-Breast09 (#1021) and DESTINY-Gastric04 (#4111) phase 3 trials of Enhertu® (trastuzumab deruxtecan), and the TROPION-Breast02 (#1002) phase 3 trial of Datroway® (datopotamab deruxtecan). Additional results from earlier phase trials as well as trials-in-progress across new medicines being developed through the company’s breakthrough generating technology (BGT), a platform-based drug discovery model designed to deliver innovative medicines ...